Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan (5‑HT1B/1D receptor agonist) presented as a nasal spray for nasal use. It treats acute migraine attacks in adults.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory‑compliant distribution, and dedicated technical support.

Sumatriptan is a selective 5‑HT1B/1D receptor agonist used for acute migraine management.

- Migraine with aura: provides rapid relief of headache pain and associated symptoms when taken at the onset of an attack. - Migraine without aura: reduces headache intensity, nausea, photophobia and phonophobia when administered early. - Cluster headache: offers acute relief of severe unilateral head pain during an episodic cluster period.

Common Side Effects: - Nasal irritation or burning sensation - Unpleasant taste or metallic after‑taste - Dizziness or light‑headedness - Somnolence or mild fatigue - Nausea or mild stomach discomfort - Dry mouth

Serious or Rare Side Effects: - Chest pain or coronary vasospasm - Myocardial infarction or other cardiac ischemic events - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially with serotonergic agents - Anaphylactic or severe allergic reactions - Persistent visual disturbances

Before using Imigran, consider the following precautions: - Cardiovascular disease: avoid if you have coronary artery disease, angina, or a history of myocardial infarction. - Uncontrolled hypertension: do not use if blood pressure is not adequately controlled. - Hemiplegic or basilar migraine: contraindicated in these migraine subtypes. - Concomitant MAO‑inhibitors or ergot derivatives: avoid co‑administration due to increased risk of vasospasm. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at room temperature: keep in the original packaging, protect from moisture and direct heat.

Sumatriptan may interact with several drug classes.

Major Interactions (Avoid): - MAO‑inhibitors (e.g., phenelzine, tranylcypromine): risk of severe hypertension and serotonin syndrome. - Other triptans or ergot alkaloids: additive vasoconstrictive effects. - SSRIs, SNRIs, or other serotonergic agents: increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers or other antihypertensives: may enhance blood pressure‑lowering effects. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase sumatriptan plasma levels. - Oral contraceptives: may slightly alter migraine response; monitor efficacy.